2024 CHIF Series Event: Precision Medicine and Innovative Medical Device Roadshow Successfully Held

On October 31, the “Precision Medicine and Innovative Medical Device Project Roadshow,” a key event of the 2024 Changping Pharmaceutical and Health Financial Investment Innovation Forum, was successfully held. The event was guided by the People’s Government of Changping District, Beijing, and Beijing State-owned Capital Operation and Management Co., Ltd., and jointly organized by the Future Science City Management Committee (Life Science Park Management Committee), the Zhongguancun Science Park Changping Park Management Committee, the Changping District Development and Reform Commission, Changping Development Group, and VCBeat VB100.

The event featured on-site pitch presentations of high-quality projects in fields such as intelligent 3D medical printing systems, gene sequencing and data analysis, digital services, and innovative medical devices. It invited investment firms including Daoyuan Capital, FreeS Fund, Jianggen Capital, and Jinhuitong Investment to provide expert commentary, with representatives from over 40 venture capital firms, financial institutions, and high-growth enterprises attending for networking and exchange.

At the outset of the event, Zhang Xin, Deputy Director of the Life Sciences Services Division of the Future Science City Management Committee (Life Science Park Management Committee), introduced Changping District’s favorable business environment, enterprise-friendly policies, industrial clustering, ecosystem development, and supporting services for the pharmaceutical and health industries. She expressed her hope that such events would build a bridge between venture capital firms and projects, facilitating precise matching and collaboration between presenting companies and investors, and welcomed high-quality enterprises and institutions to explore opportunities and invest in Changping.

During the roadshow session, seven high-quality projects engaged in in-depth discussions with investment institutions on multiple dimensions, including technology, team, market, business model, and future strategic development plans. The investors also provided targeted recommendations and financing planning strategies for the enterprises.

Alanbell distinguishes itself through its innovative digital health management model and personalized services. Its proprietary, self-developed algorithms automatically analyze physical examination and test results, applying evidence-based medicine principles to interpret correlated findings for clinical disease risk identification, thereby making disease risks “quantifiable, visualizable, and manageable.” Leveraging its online digital health marketplace, the company offers lightweight health management products, enabling a fully digitalized customer journey encompassing purchase, experience, and management. Supported by an international team of experts and high-standard laboratories, Alanbell provides dual-membership management services in China and the United States. By integrating globally leading testing equipment and algorithmic technologies in the field of specialized testing, it delivers specific and differentiated diagnostic solutions for the prevention, early diagnosis, and management of chronic diseases.

Jingchuang Haoda focuses on the research and application of precision personalized diagnosis and treatment technologies. Leveraging technical support from expert advisors at institutions such as the Artificial Intelligence and Medical Robotics Laboratory of West China Hospital, Sichuan University, the company is committed to the R&D and industrialization of key technologies in minimally invasive surgery, navigation, puncture, human-machine collaboration, and smart materials. The team has independently developed an intelligent 3D ultra-high-speed medical printing system that provides precise, personalized external fixation treatments for trauma emergencies and postoperative immobilization. Built upon AI-driven print path control systems and underlying cold-curing, support-free printing technology, this system achieves printing and curing efficiencies more than 20 times greater than those of traditional 3D printing technologies, with the fastest print-to-fit time being just 15 minutes—a world-first innovation.

Puyi Bio specializes in providing leading domestic nanopore sequencing technology solutions. Based on the principle of biological nanopore gene sequencing, and integrating semiconductor integrated chips, deep learning, and genomics technologies, the company develops nanopore gene sequencers along with配套 reagents and consumables. Its core products include the medium-throughput nanopore sequencer PolyseqOne, the sequencing chip PolyseqCell, and a variety of sequencing kits for different applications. The company is about to launch PolyseqHive, a higher-throughput platform. Characterized by single-molecule sequencing, long-read output, electrical signal detection, and PCR-free amplification, nanopore sequencing technology represents the latest advancement in gene sequencing. This technology interprets sequences by analyzing the obstruction of ionic current as DNA or other molecules pass through nanopores, enabling broad applications in genomics, new drug development, microbial detection, early cancer screening, and other fields. Puyi Bio is committed to driving China’s gene sequencing industry from its source, bringing sequencing technology into medical institutions at all levels, transforming disease diagnosis and treatment models, safeguarding public life and health, and meeting the demands of precision medicine in the era of big data.

Medtop specializes in providing comprehensive therapeutic solutions for cardiovascular diseases. Since its establishment in 2005, the company has continuously innovated and secured over 200 patents, including more than 60 invention patents and overseas PCT patents. Medtop has pioneered multiple first-in-China products in the treatment of cardiovascular conditions such as electrophysiological disorders, congenital heart disease (CHD), and valvular heart disease. These innovations include a radiofrequency ablation system for atrial fibrillation (AF) treatment, a left atrial appendage closure system for stroke prevention, and the world’s only pulmonary artery stent. The company’s product portfolio is designed to offer comprehensive treatment solutions for physicians and patients, encompassing integrated heart-brain management and stroke intervention for AF; neonatal rescue and lifelong intervention for CHD; and anatomical correction along with improvement of cardiac function for valvular heart disease. Medtop’s products have not only achieved breakthroughs in the domestic market but are also expanding globally, with five products having obtained CE certification and sales networks established in Southeast Asia, Europe, and other regions.

Hengyu Medical focuses on the development of intelligent diagnostic and therapeutic devices for endovascular interventions. Leveraging its technology platforms in optics, ultrasound, and artificial intelligence, the company holds over 165 invention patents, including international PCT patents. Its product portfolio encompasses intravascular ultrasound (IVUS) systems and catheters, optical coherence tomography (OCT) systems and catheters, dual-catheter systems based on an integrated IVUS/OCT platform, non-invasive fractional flow reserve (FFR) platforms utilizing IVUS and OCT, independently developed single-source dual-modality OCT-NIRS technology combining OCT with near-infrared spectroscopy, and intravascular laser plaque ablation technology. Hengyu Medical masters core technologies in optics, ultrasound, and catheter platforms, continuously driving globally leading innovations based on these foundational technologies. The company is committed to providing healthcare professionals and patients with pan-vascular integrated solutions centered on imaging-based products. Clinically applied to the diagnosis and treatment of coronary artery disease, these solutions offer high-resolution imaging and deeper penetration depth, assisting physicians in surgical decision-making and assessment.

Tonghe Litai is the only barrier-level large animal experimental facility in China, specializing in large animal studies primarily using miniature pigs. As the first large animal experimental platform in China to meet Good Laboratory Practice (GLP) standards for the preclinical evaluation of medical devices, it provides comprehensive services spanning scientific research, technological support, and clinical training, covering all categories of Class III medical devices. The platform features advanced facilities, including an interventional laboratory, a surgical laboratory, a small and large animal model care center, and a training hall. Its industry-leading position is demonstrated by five consecutive years with zero findings issued in animal study reports. Tonghe Litai is committed to providing a one-stop service process ranging from proof-of-concept and biocompatibility testing to preclinical device evaluation. By serving hospitals, research institutions, and medical device companies, it facilitates the translation of scientific achievements, accelerates regulatory approval for enterprises, and expedites product adoption in hospitals, thereby driving innovation and development in the medical device industry.

Zhongke Borui is dedicated to the research, development, and provision of diagnostic and therapeutic devices for brain disorders, with a particular focus on the detection and treatment of stroke (cerebral infarction). Its product portfolio covers early warning, intermediate monitoring, and rehabilitative therapy for stroke, aiming to improve treatment outcomes and quality of life for stroke patients. Leveraging the scientific research strengths of the Institute of Automation, Chinese Academy of Sciences, the company translates brain science technologies—such as brain atlases, brain-computer interfaces, and brain intelligence—into clinical application tools. The company’s products include non-invasive cerebral oximeters and wireless cerebral oxygenation monitoring headbands, which utilize near-infrared spectroscopy technology to achieve real-time monitoring of cerebral oxygen saturation, providing early warning and assessment of cerebral tissue oxygenation during the perioperative and critical care periods. Furthermore, the company has developed a photoelectric synchronous brain function imager that combines electroencephalography (EEG) and cerebral oxygenation monitoring technologies to enable simultaneous monitoring of multiple brain regions, thereby providing a scientific basis for rehabilitation training in stroke patients.

Following the event, the on-site networking atmosphere was vibrant. Institutional representatives engaged in in-depth discussions with the pitched projects regarding potential business collaborations. Attendees expressed strong appreciation for the high quality of the showcased projects and the efficient format of the event, generating enthusiastic feedback. This series of roadshows aims to establish a matchmaking and exchange platform connecting projects with industry players and investors. By aggregating essential resources for project growth, it seeks to further support innovative ventures and inject new vitality into the high-quality development of the pharmaceutical and health industries.